Abstract:Abstract Background: While PD-(L)1 inhibitors have improved outcomes for melanoma, a substantial proportion of patients do not respond or develop resistance. Sitravatinib, a spectrum-selective TKI targeting TAM receptors (Tyro3/Axl/MerTK) and VEGFR2, reduces the number of myeloid-derived suppressor cells and regulatory T cells while increasing the ratio of M1/M2-polarized macrophages, which may overcome an immunosuppressive tumor microenvironment and augment antitumor immune responses. Tislelizumab, an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, has shown clinical activity as a single agent and in combination with chemotherapy in patients with advanced solid tumors, including melanoma. Methods: We report results from the melanoma cohort of an ongoing multicohort phase 1b study (BGB-900-103; NCT03666143) assessing safety/tolerability and preliminary antitumor activity of sitravatinib + tislelizumab in advanced solid tumors. Eligible patients had unresectable or metastatic melanoma refractory/resistant to PD-(L)1 inhibitors and had not received other prior immunotherapy (eg, anti-CTLA-4, -OXO40, or -CD137) or anti-BRAF/MEK therapy. Patients received oral sitravatinib 120 mg once daily and tislelizumab 200 mg IV Q3W until a discontinuation criterion was met. The primary endpoint was safety/tolerability; key secondary endpoints included investigator-assessed objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Results: As of Oct 13, 2020, 25 patients were enrolled; 16 patients (64%) remained on treatment. All patients received 1 prior line of PD-(L)1 therapy, median age was 51 years (range: 23-79), and baseline histology included cutaneous (n=12; 48%), acral (n=7; 28%), and mucosal (n=4; 16%) subtypes. Median duration of study follow-up was 5.5 months (range: 1.5-13.3). Adverse events (AEs) were reported in 25 patients (100%); the most commonly reported grade ≥3 AE was hypertension (n=3; 12%). Serious AEs were reported in 4% (n=1/25) of patients. Dose reductions of sitravatinib due to AEs occurred in 13 patients. No AEs led to death. Six patients achieved a confirmed partial response. Confirmed ORR was 24.0% (95% CI: 9.36-45.13); DCR was 88.0% (95% CI: 68.78-97.45). Median PFS was 6.7 months (95% CI: 4.07, not evaluable). Conclusions: Sitravatinib + tislelizumab was generally well tolerated, had a manageable safety/tolerability profile, and demonstrated preliminary antitumor activity in patients with refractory/resistant unresectable or metastatic melanoma. Further investigation of sitravatinib + tislelizumab in these patients is warranted. Citation Format: Chuanliang Cui, Hongming Pan, Matteo Carlino, Jiuwei Cui, Xuan Wang, Cheng Chen, Xiao Xiang, Liu Yang, Jun Guo. Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT035.

1055P Safety and Activity of SmarT Cells Plus PD-1 Blocking Antibodies in Patients with Heavily Pretreated Solid Cancers: an Open-Label and Dose-Escalation Study

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

A Phase Ia/Ib Trial of the Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mab), CS1001, in Patients (pts) with Advanced Solid Tumours or Lymphomas

Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients

Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

Peripheral blood–derived PD-1/CD28–CD19-CAR–modified PD-1+ T-cell therapy in patients with solid tumors

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients

Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Safety, Efficacy, and Biomarker Analysis of Response to Engineered Tumor-Infiltrating Lymphocytes Secreting Anti-Pd-1 Antibody in Recurrent Glioblastoma: an Open-Label, Two-Arms, Phase 1 Study

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

A Phase I Study of an IDO Inhibitor (SHR9146) Plus Camrelizumab and in Combination With/without Apatinib in Patients with Advanced Solid Tumors: Safety and Efficacy Analysis.

Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.

Abstract LB071: Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors

A Phase 1, First-in-human, Open-Label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

1026MO A Phase Ib/II Study of SHR-1701 (a Bifunctional Anti-Pd-l1/tgf-βrii Agent) in Combination with Bevacizumab (BEV) in Patients with Advanced Solid Tumors

The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841).

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

Abstract CT035: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study